Personalized and Precision Medicine (PPM) has being the grand challenge to forecast, to personalize, to predict and to prevent is rooted in a big and a new science generated by the achievements of Systems Biology and Translational Armamentarium whilst integrating OMICS platforms and Bioinformatics as well.The development and application of systems strategies to biology and disease are transforming medical research and clinical practice in an unprecedented rate. Translational research is the science that aims at making scientific discoveries available for application in relation to life sciences, medicine, bio-design and bioengineering. Translational Medicine (TM) is thus an area of research and applications that aims to improve human health and longevity by determining the relevance to human disease of novel discoveries as applicable to PPM.TM seeks to coordinate the use of new knowledge in clinical practice, biotech and biopharma and to incorporate clinical observations and questions into scientific hypotheses in the laboratory. Thus, it is a bidirectional concept, encompassing so called bench-to-bedside factors, which aim to increase the efficiency by which new diagnostic, predictive, prognostic & therapeutic strategies developed through basic research are tested clinically, and bedside-to-bench factors, which provide feedback about the applications of new treatments and how they can be improved. TM facilitates the characterization of disease processes based on monitoring of biomarkers-related dynamics and the generation of novel hypotheses based on direct human observation.PM as being as a model of healthcare services to be updated via the new philosophy and translational bridges, would unite patients and persons-at-risk, community health service centers, hospitals, remote clinics, and education centers to improve the quality and efficiency of healthcare.So, the goals of PM and TM as a tandem in academia and bio-industry are complementary. Thus, a balanced approach that encourages partnership between those entities could establish a positive feedback loop in which benefits raised in academia would lead to the development of new products in bio-industry and then to be implemented in clinical practice.To optimize translational research, policy could consider refining translational research models to better reflect scientists' experiences, fostering greater collaboration to suit strategic alliances and buy in from all types of scientists.